Skyrizi came out on top with the latest quarterly crown for over-the-counter (OTC) pharma and Rx brands. The AbbVie treatment for psoriasis, Crohn’s disease and psoriatic arthritis finished in first ...

As we hit the middle of the year, AbbVie is comfortably back in the top TV drug ad spenders’ driving seat taking the top two spots in July with its immunology blockbuster duo Skyrizi and Rinvoq, ...

AbbVie is once again the top spender on pharma TV ads, narrowly beating April's winner, Rexulti. That’s according to the latest data from real-time TV ad trackers at iSpot.TV, who crunched May’s ...

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer immunology medicines, Skyrizi and Rinvoq. Investors will be most keen to know ...